A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 25, 2018

Primary Completion Date

April 16, 2018

Study Completion Date

April 16, 2018

Conditions

Healthy Volunteers

Interventions

DRUG

BGB-3111

Subjects will receive BGB-3111

DRUG

Placebo

Subjects will receive Placebo

DRUG

Moxifloxacin

Subjects will receive Moxifloxicin

Trial Locations (1)

Frontage Clinical Services, Inc., Secaucus